Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Operating Margin (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Operating Margin for 2 consecutive years, with 307.59% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 53819.0% to 307.59% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 861.33% through Dec 2025, up 113458.0% year-over-year, with the annual reading at 861.33% for FY2025, 113458.0% up from the prior year.
  • Operating Margin hit 307.59% in Q4 2025 for Prelude Therapeutics, up from 314.12% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 307.59% in Q4 2025 to a low of 1145.87% in Q3 2024.